LAUSR

Highlights • Hypoxia has long been recognised as a major cause of treatment failure in solid tumour and is a crucial feature of aggressive tumours.• Head and neck cancers have limited treatment options and remain dependent on radiotherapy, hypoxic adaption is particularly restrictive to RT success.• To reverse, correct or diminish hypoxia has important benefits in treatment sensitization of head and neck cancers to RT, chemo- and immunotherapy.• We provide an overview of all main strategies to target tumor hypoxia: HIF-inhibitors, hypoxia-activated prodrugs, and anti-angiogenic agents.• We underline emerging strategies towards efficient delivery of drugs to combat restrictive microenvironment of hypoxic tumour tissue.